FASEB J. Cell Migration Consortium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campana, W. M.
Right arrow Articles by O'Brien, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campana, W. M.
Right arrow Articles by O'Brien, J. S.
(The FASEB Journal. 1998;12:307-314.)
© 1998 FASEB

RESEARCH COMMUNICATION

Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells

W. Marie Campanaa, Masao Hiraiwaa, and John S. O'Briena,1

a Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, California 92093, USA

Prosaposin, the precursor of saposins A, B, C, and D, was recently reported to be a neurotrophic factor in vivo and in vitro. The neurotrophic region of prosaposin has been localized to a 12-amino acid sequence within the saposin C domain and has been used to derive biologically active synthetic peptides (14–22 residues), called prosaptides. Treatment of primary Schwann cells and an immortalized Schwann cell line, iSC, with a 14-mer prosaptide, TX14(A) (10 nM), enhanced phosphorylation of mitogen-activated kinases ERK1 (p44 MAPK) and ERK2 (p42 MAPK) within 5 min, which was blocked by 4 h pretreatment with pertussis toxin. Furthermore, incubation of Schwann cells with the nonhydrolyzable GDP analog GDP-ßS inhibited TX14(A)-induced ERK phosphorylation. TX14(A) enhanced the sulfatide content of primary Schwann cells by 2.5-fold, which was inhibited by pretreatment with pertussis toxin or the synthetic MAP kinase kinase inhibitor PD098059. In addition, TX14(A) increased the tyrosine phosphorylation of all three isoforms of the adapter molecule, Shc, which coincided with the association of p60Src and PI(3)K. Inhibition of PI3(K) by wortmannin blocked TX14(A)-induced ERK phosphorylation. These data demonstrate that TX14(A) uses a pertussis toxin-sensitive G-protein pathway to activate ERKs, which is essential for enhanced sulfatide synthesis in Schwann cells.—Campana, W. M., Hiraiwa, M., O'Brien, J. S. Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J. 12, 307–314 (1998)


Key Words: prosaposin • saposin C • myelin • MAP kinase • PI3 kinase




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
E. Mantuano, G. Mukandala, X. Li, W. M. Campana, and S. L. Gonias
Molecular Dissection of the Human {alpha}2-Macroglobulin Subunit Reveals Domains with Antagonistic Activities in Cell Signaling
J. Biol. Chem., July 18, 2008; 283(29): 19904 - 19911.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
W. M. Campana, X. Li, N. Dragojlovic, J. Janes, A. Gaultier, and S. L. Gonias
The Low-Density Lipoprotein Receptor-Related Protein Is a Pro-Survival Receptor in Schwann Cells: Possible Implications in Peripheral Nerve Injury
J. Neurosci., October 25, 2006; 26(43): 11197 - 11207.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Piatigorsky, B. Norman, L. J. Dishaw, L. Kos, J. Horwitz, P. J. Steinbach, and Z. Kozmik
J3-crystallin of the jellyfish lens: Similarity to saposins
PNAS, October 23, 2001; 98(22): 12362 - 12367.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
C. G. Schuette, B. Pierstorff, S. Huettler, and K. Sandhoff
Sphingolipid activator proteins: proteins with complex functions in lipid degradation and skin biogenesis
Glycobiology, June 1, 2001; 11(6): 81R - 90R.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
H. Hulkova, M. Cervenkova, J. Ledvinova, M. Tochackova, M. Hrebicek, H. Poupetova, A. Befekadu, L. Berna, B.C. Paton, K. Harzer, et al.
A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation
Hum. Mol. Genet., April 1, 2001; 10(9): 927 - 940.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
R. MISASI, M. SORICE, L. DI MARZIO, W. M. CAMPANA, S. MOLINARI, M. G. CIFONE, A. PAVAN, G. M. PONTIERI, and J. S. O'BRIEN
Prosaposin treatment induces PC12 entry in the S phase of the cell cycle and prevents apoptosis: activation of ERKs and sphingosine kinase
FASEB J, February 1, 2001; 15(2): 467 - 474.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. M. Taylor, D. A. Otero, W. A. Banks, and J. S. O'Brien
Retro-Inverso Prosaptide Peptides Retain Bioactivity, Are Stable In Vivo, and Are Blood-Brain Barrier Permeable
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 190 - 194.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. M. Taylor, D. A. Otero, W. A. Banks, and J. S. O'Brien
Designing Stable Blood-Brain Barrier-Permeable Prosaptide Peptides for Treatment of Central Nervous System Neurodegeneration
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 403 - 409.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
Q. Zhao and C. R. Morales
Identification of a Novel Sequence Involved in Lysosomal Sorting of the Sphingolipid Activator Protein Prosaposin
J. Biol. Chem., August 4, 2000; 275(32): 24829 - 24839.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by The Federation of American Societies for Experimental Biology.